Printer Friendly

LexisNexis Experts Program Offers Litigation Authorities Re Vioxx.

DAYTON, Ohio -- The first jury verdict is in against Merck's Vioxx arthritis drug. The second trial begins Sept. 12 in Atlantic City, NJ, home state of corporate pharmaceutical giant Merck where LexisNexis experts say Merck has the probability of doing "better" perhaps due to:

--A more affluent and/or sympathetic jury

--Favorability re home-state status

--Examples in the first trial from which to learn

LexisNexis Expert News Source (LENS) makes the nation's leading attorneys, experts, authors and editors available to you for fact checking, substantiation and background perspective. We offer you:

--Michael Lefkowitz, editor of Mealey's Litigation Reports on Arthritis Drugs, Fen-Phen/Redux and Thimerosal & Vaccines.

--Roger J. Dodd, Esq., Co-author of Cross-Examination: Science & Techniques, www.lexisnexis.com/bookstore

--Larry S. Pozner, Esq., Co-author of Cross-Examination: Science & Techniques, www.lexisnexis.com/bookstore

Michael Lefkowitz can:

--Substantiate litigation coverage unfolding in Vioxx trials, report on suits as they are filed, track Vioxx litigation as it wends through state and federal courts.

--Compare Merck's Vioxx woes with Pfizer's Rezulin and Wyeth's fen-phen, if such correlations exist.

--Offer perspective on pharmaceuticals product litigation in re fen-phen, arthritis, diabetes drugs and vaccines.

Roger Dodd can:

--Discuss the up-hill climb for Merck as a multi-national corporation without a community with which to attach.

--Reflect on how corporations hire attorneys that mirror corporate values and image and whether this ever plays favorably with juries.

--Suggest three considerations for Merck to help it win in New Jersey - take responsibility, communicate the facts and tout the benefits of Vioxx.

--Confirm whether cross-examination of the plaintiff by Merck is necessary or damaging (as in the first trial).

Larry Pozner can:

--Comment on the Texas winning attorney's skills and the techniques he used.

--Offer constructive feedback re Merck's trial performance and cross-examination that would position it more favorably in New Jersey.

--Address the nuances juries look for in lawyering that helps create favorable regard from juries.

--Expound on how the business of trial litigation has changed with the onset of televised courtrooms, the Internet, lawyers on TV and attorneys using media to get ahead.

--Discuss the philosophy of wins - preparation, the science of cross-examination, connection and confidence.

Bio Sketches

Michael Lefkowitz, based in Pennsylvania, is an expert on drug product liability and litigation. For more than three years, he has researched and written stories on the pharmaceutical industry, including mass torts and major drugs. Currently he edits three Mealey's Litigation Reports (see above), and was previously editor of two Mealey's litigation reports on diabetes drugs and propulsid.

Roger Dodd is a Georgia practicing attorney, board certified by the National Board of Trial Advocacy in Civil and Criminal Trial Practice. He has been listed since 1991 in Best Lawyers in America; since 1993 in Martindale Hubbell's Bar Register of Preeminent Lawyers, and is currently listed in Georgia Super Lawyers. His more than three decades as an experienced trial attorney positions his law practice to emphasize complex litigation including national cases relating to over-the-road trucks, corporate law and catastrophic personal injury and wrongful death suits.

Larry Pozner is a leading attorney from Denver and listed in Best Lawyers in America. He is past president of the National Association of Criminal Defense Lawyers, and his law practice includes criminal defense and complex civil litigation. He is trial counsel to the Denver Broncos, and he frequently appears on national broadcast media to comment on legal issues.

About LexisNexis

LexisNexis(R) (www.lexisnexis.com) is a leader in comprehensive and authoritative legal, news and business information and tailored applications. A member of Reed Elsevier Group plc (NYSE:ENL); (NYSE:RUK) (www.reedelsevier.com), the company does business in 100 countries with 13,000 employees worldwide. In addition to its flagship Web-based Lexis(R) and Nexis(R) research services, the company includes some of the world's most respected legal publishers such as Martindale-Hubbell, Matthew Bender, Butterworths, JurisClasseur, Abeledo-Perrot and Orac.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Aug 24, 2005
Words:644
Previous Article:IMlogic Threat Center reports Tixanbot Trojan and Guapim Worm spreading over leading public IM networks.
Next Article:Xcel Energy Names Mercer Assistant Treasurer.
Topics:


Related Articles
New Cox-2 pain relievers are marketing marvel, not miracle drugs.
Mealey's launches litigation letter on defects insurance.
Mealey's launches seven titles simultaneously.
QS Labs Inc. Hosts 'The Vioxx Effect' Executive Forum, Wednesday, Dec. 8, 2004.
New resources aid Vioxx plaintiffs and their lawyers.
ATLA offers updates on Vioxx.
New resources focus on continuing Cox-2 dangers.
Section members get free research material.
Pharmaceutical litigation heats up, ATLA helps.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters